Article info
PDFReview
The changing landscape of biosimilars in rheumatology
- Correspondence to Professor Thomas Dörner, Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin &DRFZ Berlin, Chariteplatz 01, Berlin 10117, Germany; thomas.doerner{at}charite.de
Citation
The changing landscape of biosimilars in rheumatology
Publication history
- Received January 11, 2016
- Revised February 17, 2016
- Accepted February 18, 2016
- First published March 8, 2016.
Online issue publication
May 10, 2016
Article Versions
- Previous version (8 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/